Forsta AP Fonden trimmed its stake in shares of Johnson & Johnson (NYSE:JNJ) by 8.6% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 434,255 shares of the company’s stock after selling 40,700 shares during the period. Johnson & Johnson accounts for 1.6% of Forsta AP Fonden’s portfolio, making the stock its 6th largest holding. Forsta AP Fonden’s holdings in Johnson & Johnson were worth $57,448,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Lenox Wealth Advisors Inc. grew its stake in Johnson & Johnson by 0.6% during the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after acquiring an additional 5 shares in the last quarter. Lbmc Investment Advisors LLC grew its stake in Johnson & Johnson by 0.4% during the first quarter. Lbmc Investment Advisors LLC now owns 3,704 shares of the company’s stock valued at $461,000 after acquiring an additional 14 shares in the last quarter. Berson & Corrado Investment Advisors LLC grew its stake in Johnson & Johnson by 0.7% during the first quarter. Berson & Corrado Investment Advisors LLC now owns 2,835 shares of the company’s stock valued at $353,000 after acquiring an additional 19 shares in the last quarter. Cascade Investment Advisors Inc. grew its stake in Johnson & Johnson by 0.3% during the second quarter. Cascade Investment Advisors Inc. now owns 7,048 shares of the company’s stock valued at $932,000 after acquiring an additional 23 shares in the last quarter. Finally, RB Capital Management LLC grew its stake in Johnson & Johnson by 0.4% during the first quarter. RB Capital Management LLC now owns 5,559 shares of the company’s stock valued at $692,000 after acquiring an additional 24 shares in the last quarter. 66.00% of the stock is owned by institutional investors.

In related news, VP Paulus Stoffels sold 102,692 shares of the company’s stock in a transaction dated Monday, July 24th. The shares were sold at an average price of $133.14, for a total value of $13,672,412.88. Following the completion of the sale, the vice president now owns 230,342 shares of the company’s stock, valued at $30,667,733.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Dominic J. Caruso sold 82,591 shares of the company’s stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the completion of the sale, the vice president now directly owns 226,693 shares of the company’s stock, valued at approximately $30,993,466.96. The disclosure for this sale can be found here. Corporate insiders own 0.19% of the company’s stock.

Several equities analysts recently weighed in on JNJ shares. BTIG Research reaffirmed a “hold” rating on shares of Johnson & Johnson in a research note on Sunday, May 21st. Vetr raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $132.33 target price for the company in a research note on Monday, May 29th. BMO Capital Markets reaffirmed a “buy” rating and set a $132.00 target price on shares of Johnson & Johnson in a research note on Friday, June 2nd. Cowen and Company reaffirmed an “outperform” rating and set a $143.00 target price on shares of Johnson & Johnson in a research note on Tuesday, June 13th. Finally, Royal Bank Of Canada reaffirmed a “buy” rating and set a $128.00 target price on shares of Johnson & Johnson in a research note on Thursday, June 15th. Three analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $134.60.

Johnson & Johnson (JNJ) traded up 0.20% during midday trading on Friday, hitting $134.45. 15,522,011 shares of the stock traded hands. Johnson & Johnson has a 52-week low of $109.32 and a 52-week high of $137.08. The firm has a market cap of $360.86 billion, a PE ratio of 22.75 and a beta of 0.79. The stock has a 50-day moving average of $132.62 and a 200 day moving average of $129.18.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, July 18th. The company reported $1.83 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.79 by $0.04. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The firm had revenue of $18.84 billion during the quarter, compared to analyst estimates of $18.94 billion. During the same quarter in the prior year, the firm posted $1.74 earnings per share. Johnson & Johnson’s quarterly revenue was up 1.9% on a year-over-year basis. Equities analysts forecast that Johnson & Johnson will post $7.18 EPS for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 12th. Investors of record on Tuesday, August 29th were issued a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.50%. The ex-dividend date of this dividend was Friday, August 25th. Johnson & Johnson’s dividend payout ratio is currently 56.76%.

TRADEMARK VIOLATION NOTICE: “Forsta AP Fonden Cuts Position in Johnson & Johnson (JNJ)” was first posted by Daily Political and is the property of of Daily Political. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at https://www.dailypolitical.com/2017/09/17/forsta-ap-fonden-cuts-position-in-johnson-johnson-jnj.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.